Overview
RCEL market data
Price History
RCEL price chart · 1M
- O
- 10.25
- H
- 10.46
- L
- 10.23
- C
- 10.39
- Vol
- 7,977.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $10.25
- Previous Close
- $10.57
- Day High
- $10.46
- Day Low
- $10.23
- 52 Week High
- $10.75
- 52 Week Low
- $3.74
- 7 Day Return
- +3.03%
- 30 Day Return
- +125.27%
- 90 Day Return
- +140.95%
- 1 Year Return
- +146.09%
- Daily Notional Volume
- $82.8K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.74 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.01 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -62.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.22 – $10.77 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $306.5M · P/B 74.59 · P/S 4.24.
Company News
TD Cowen Maintains Buy on AVITA Medical, Raises Price Target to $14Benzinga · Aug 19, 2026, 3:10 PM
BTIG Maintains Buy on AVITA Medical, Raises Price Target to $11Benzinga · Aug 19, 2026, 12:29 PM
AVITA Medical shares are trading higher after the company announced its PermeaDerm-I study met primary endpoint, delivering clinically comparable outcomes to cadaveric allograft with 70% cost reduction.Benzinga · Aug 18, 2026, 5:19 PM
AVITA Medical Announces PermeaDerm-I Study Met Primary Endpoint, Delivering Clinically Comparable Outcomes To Cadaveric Allograft With 70% Cost ReductionBenzinga · Aug 18, 2026, 11:47 AM
12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga · Aug 7, 2026, 5:05 PM
AVITA Medical Announces Participation at Canaccord Genuity Growth ConferenceGlobenewswire Inc · Aug 7, 2026, 1:15 PM
AVITA Medical shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.Benzinga · Aug 7, 2026, 12:50 PM
12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga · Aug 7, 2026, 12:05 PM
This SpaceX Analyst Turns Bullish; Here Are Top 5 Upgrades For FridayBenzinga · Aug 7, 2026, 12:05 PM
BTIG Upgrades AVITA Medical to Buy, Announces $7 Price TargetBenzinga · Aug 7, 2026, 10:13 AM